Led · Series B · Mar 2024

Protembis develops the ProtEmbo Cerebral Protection System, an intra-aortic filter delivered via the left radial artery to deflect embolic material away from cerebral arteries during transcatheter aortic valve replacement (TAVR) and other left-sided heart procedures. The company is advancing ProtEmbo through clinical investigations, including a pivotal FDA‑approved Investigational Device Exemption (IDE) study intended to enroll 250–500 patients in Europe and the US. Protembis is using recent financing to support clinical trials, research and development, and market access for the next‑generation device. Financially, the company completed a €30 million Series B in March 2024 and has secured an additional €20 million venture‑debt facility from the European Investment Bank. The EIB financing is supported by the InvestEU programme and is intended to accelerate product development and regulatory pathways. Protembis is a privately held emerging medtech based in Aachen, Germany. Protembis has developed the ProtEmbo® Cerebral Protection System, an intra-aortic filter device designed to protect the entire brain from embolic material liberated during transcatheter aortic valve replacement (TAVR). The low-profile, non-thrombogenic system shields all cerebral vessels and is delivered via the left radial artery to avoid interference with femoral-delivered TAVR equipment. The ProtEmbo System is currently undergoing clinical investigations, including the PROTEMBO IDE Pivotal Trial (NCT05873816). Protembis says its technology aims to reduce brain injury during left-sided heart procedures, improve patient quality of life, and lower healthcare costs associated with such injuries. The company is privately held and headquartered in Aachen, Germany. Recent financing activity is intended to support the ongoing pivotal trial and pre-commercial programs. Protembis has developed the ProtEmbo, a catheter-based filter advanced via the radial artery to cover arteries leading to the brain while allowing blood cells to pass and blocking embolic particles; the filter is heparin-coated to reduce clotting. The device is designed to minimize particle migration to the brain during transcatheter aortic valve implantation (TAVI/TAVR) and other interventional heart procedures. Protembis reported initial safety and feasibility and demonstrated effectiveness in a first-in-human clinical study. The company plans further clinical studies at leading heart centers in Europe and the U.S. and aims to bring the ProtEmbo to market maturity. Protembis emphasizes a large and growing market opportunity driven by demographic trends and increased use of minimally invasive heart valve interventions. The company has closed institutional backing via a recent Series A to fund development toward commercialization.

Led · Equity · Aug 2023

Collective Minds Radiology builds a cloud-based collaboration platform for healthcare that provides access to data as well as human and digital expertise for clinical consultation, education, and research. The company offers products and services focused on medical imaging research, clinical consultation, and education. Founded in 2017 and led by CEO Andre Nordell, the Stockholm-based health-tech startup has connected over 14,000 healthcare professionals and 170 healthcare providers and hospitals to its platform. In August 2023 it closed SEK84M (approx. USD7.615M) in financing. The company intends to use the proceeds to accelerate commercial expansion of its professional healthcare collaboration platform. No other financial details were disclosed in the article. Collective Minds Radiology develops a cloud‑based healthcare collaboration service that enables doctors, researchers and industry to collaborate across borders on medical imaging, consultations, clinical trials and education. The platform today connects 50 hospitals and more than 2,000 doctors. The company says demand has grown during the pandemic as hospitals and specialists seek better digital collaboration. Collective Minds has commercial and clinical management in Stockholm and product development in Barcelona. The recently raised capital will support continued technology development, expansion of the team, further European expansion and preparations for a global launch. The company positions itself as building a network of collective and artificial intelligence in radiology to improve diagnosis and clinical research.

Led · Series A · Jul 2022

Navinci Diagnostics (formerly Olink Bioscience) develops and markets in situ proximity ligation assays for detecting proteins, their interactions, and post-translational modifications in tissue and cell samples. The company's initial focus is on immuno-oncology research and drug development. It is led by CEO Robert Gunnarsson. Navinci plans to soon launch the first commercially available assay to accurately detect PD‑1/PD‑L1 interactions in tissue samples. The company intends to use new funding to accelerate international commercialization and to form partnerships with pharma companies and firms with complementary technologies to offer complete solutions for customers. The recent Series A strengthens its position as it moves toward broader market entry.

Participated · Equity · Mar 2022

Signifier develops and commercializes eXciteOSA, a daytime neuromuscular electrical stimulation (NMES) device that exercises tongue muscles to reduce airway collapse during sleep. eXciteOSA is the first commercially available device intended for use while awake and has been launched in the United States, Canada, the United Kingdom and Germany. The company positions its therapies to improve population health, patient experience and generate healthcare savings. Signifier was founded in 2015 and maintains offices in London (UK), Needham, Massachusetts (USA) and Berlin (Germany). Management cites successful commercial launches and positive patient outcomes as drivers of growth. The company says it is working to secure funding required to finance future growth. Signifier’s core product is eXciteOSA, an FDA-approved De Novo device that uses neuromuscular electrical stimulation (NMES) of tongue and pharyngeal muscles and is guided by a proprietary smartphone app. The device is used while awake, rests on the tongue, and aims to improve muscle tone, strength and endurance to prevent airway collapse. Signifier reports high adherence (>80%) and over 25,000 successfully completed daily therapies recorded through its app. The company raised $35 million in a Series D capital raise to underpin commercialization of eXciteOSA. Proceeds are earmarked for commercialization in core target markets, continued development of digital patient and physician interface platforms, generation of additional clinical data, and progressing reimbursement. Signifier was founded in 2015 and has offices in London, Needham (Massachusetts, USA) and Berlin. Signifier Medical Technologies is a medical technology company focused on non-invasive solutions for snoring and sleep disordered breathing. Its proprietary daytime genioglossal muscle‑neurostimulation therapy is commercialized as the eXciteOSA® device for mild obstructive sleep apnea, and it also markets the Snoozeal® device for primary snoring. The company is building operations and infrastructure to prepare for global commercialization of eXciteOSA while expanding commercialization of Snoozeal. Signifier is led by CEO and co‑founder Akhil Tripathi and COO Philip Hess, with Matt Sharris heading North American sales and Steve Saunders leading EMEA sales, and is based in Boston, US. It closed an approx. $10M Series C to support continued product development and commercial roll‑out. The funds will be used to invest further in its non‑invasive therapies and to accelerate the commercial phase of its development efforts. Signifier Medical Technologies, previously known as Snoozeal, is a London-based medical technology company focused on non-invasive solutions for snoring and sleep disordered breathing. Led by co-founder and Chief Medical Officer Prof. Anshul Sama, the company is developing the 'Snoozeal' neurostimulation device to address snoring and mild obstructive sleep apnoea (OSA). The company intends to use recent funding to accelerate data generation in ongoing clinical trials and to complete the FDA approval process, with a de novo filing anticipated in H2 2019. It also plans to expand its product range, including adding advanced analytics capabilities, and to grow its team to broaden commercial readiness in key geographies. Since its founding in 2015, Signifier has raised a total in excess of $13 million.

Participated · Series D · Jun 2021

Quanta Dialysis Technologies develops the Quanta Dialysis System to transform kidney care by enabling dialysis across multiple care settings. The system provides clinical versatility to perform intermittent hemodialysis (IHD), sustained low efficiency dialysis (SLED) and CRRT without bags, and in 2024 received FDA clearance for home hemodialysis with a high dialysate flow (500 mL/min). The device is designed to be operated by a broad range of users to bring dialysis directly to patients. Led by CEO Alejandro Galindo and based in Warwick, UK, the company aims to make dialysis accessible to every patient, in every setting. Quanta recently closed a Series E raising over $60M to support its US commercial expansion. The company plans to continue investing in innovation within the sector and scale its commercial footprint with support from new and existing investors. Quanta’s lead product, SC+, is a small, portable hemodialysis system that delivers the performance and dose equivalence of larger traditional machines while offering on‑demand dialysate production, high dialysate flow rates, digital connectivity and ease of use. The system uses a patented disposable cartridge for dialysate fluid management and pairs with a companion water‑purification module to create an all‑in‑one mobile stack that can run on a standard water supply. SC+ is FDA 510(k) cleared in the U.S. for use in acute and chronic care facilities and is CE marked in the U.K., where it has been used from ICU to clinic to the home. Quanta plans to scale global operations with a focus on the United States, investing in manufacturing, sales and customer service to support current approvals and market penetration. The company is preparing to launch a study to support future FDA clearance for in‑home use. The market opportunity is sizable, with a U.S. total addressable market projected to exceed $12 billion. The company is trans‑Atlantic, headquartered in the U.K. with operations in the U.S., and is now better capitalized following a major Series D raise. Quanta Dialysis Technologies develops SC+, a compact haemodialysis system designed for use in clinics and the home to empower patients to control their renal replacement therapy. The device uses a patented design that conducts all dialysate fluid management on a small, lightweight, disposable cartridge. SC+ is CE marked and has been piloted with the NHS, demonstrating clinical efficacy and performance compatible with traditional in-centre regimens. The company plans a UK commercial launch of SC+ and intends to submit a 510(k) to the FDA later this year. Quanta is led by CEO John E. Milad and was founded in 2008 in Alcester, Warwickshire, UK. The firm recently completed a first closing of Series C financing to support these plans. Quanta Fluid Solutions develops advanced haemodialysis systems, including its CE-marked portable, compact cartridge-based system called SC+. The company aims to expand its product line by developing a new nocturnal haemodialysis product concept using its cartridge platform. Funds from a £1.85M i4i award will support that development and advanced multi-physics modelling work. Quanta is collaborating with Professor William Zimmerman (Sheffield University) and Europlaz Technologies Ltd to advance cartridge technologies and modelling. Founded in 2008 as a spin-out from IMI plc, the company is based in Alcester, UK. Quanta has previously received funding from venture investors including NBGI Ventures, Wellington Partners, Seroba Kernel, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company. Quanta Fluid Solutions develops SC+, a portable, compact haemodialysis system intended for use in clinics and the home. The company is led by CEO John E. Milad and is based in Alcester, UK. It was founded in 2008 as a spinout from FTSE 100 engineering company IMI plc. Quanta focuses on enabling dialysis outside traditional centres by delivering a compact, clinic- and home-capable platform. The company closed approximately £27m in funding. It intends to use the proceeds for the clinical introduction and commercial launch of SC+.